Acquired factor VIII inhibitor in a patient with dermatomyositis - A case study

Ayodele Ayoola, Wajahath Mohsini, Sein Aung

    Research output: Contribution to journalArticle

    4 Citations (Scopus)

    Abstract

    Background: Acquired factor VIII inhibitor is an antibody formed against FVIII and seen in patients without FVIII replacement therapy. This entity has been associated with both autoimmune disease and infections. Case Study: We report the case of a 65-year-old man with dermatomyositis who presented with a bleeding episode following venipuncture and hematuria. His coagulation parameters were followed as well as the inhibitor level. His acquired FVIII inhibitor was managed successfully with rituximab. Conclusion: Our patient's bleeding episodes resolved and the inhibitor level was undetectable after 12 months. This is the first case of acquired FVIII inhibitor in association with dermatomyositis.

    Original languageEnglish (US)
    Pages (from-to)8-11
    Number of pages4
    JournalActa Haematologica
    Volume119
    Issue number1
    DOIs
    StatePublished - Mar 1 2008

    Fingerprint

    Dermatomyositis
    Factor VIII
    Hemorrhage
    Phlebotomy
    Hematuria
    Autoimmune Diseases
    Antibodies
    Infection
    Therapeutics
    Rituximab

    All Science Journal Classification (ASJC) codes

    • Hematology

    Cite this

    Ayoola, Ayodele ; Mohsini, Wajahath ; Aung, Sein. / Acquired factor VIII inhibitor in a patient with dermatomyositis - A case study. In: Acta Haematologica. 2008 ; Vol. 119, No. 1. pp. 8-11.
    @article{271b2b39576441efbd64754156b50b33,
    title = "Acquired factor VIII inhibitor in a patient with dermatomyositis - A case study",
    abstract = "Background: Acquired factor VIII inhibitor is an antibody formed against FVIII and seen in patients without FVIII replacement therapy. This entity has been associated with both autoimmune disease and infections. Case Study: We report the case of a 65-year-old man with dermatomyositis who presented with a bleeding episode following venipuncture and hematuria. His coagulation parameters were followed as well as the inhibitor level. His acquired FVIII inhibitor was managed successfully with rituximab. Conclusion: Our patient's bleeding episodes resolved and the inhibitor level was undetectable after 12 months. This is the first case of acquired FVIII inhibitor in association with dermatomyositis.",
    author = "Ayodele Ayoola and Wajahath Mohsini and Sein Aung",
    year = "2008",
    month = "3",
    day = "1",
    doi = "10.1159/000112838",
    language = "English (US)",
    volume = "119",
    pages = "8--11",
    journal = "Acta Haematologica",
    issn = "0001-5792",
    publisher = "S. Karger AG",
    number = "1",

    }

    Acquired factor VIII inhibitor in a patient with dermatomyositis - A case study. / Ayoola, Ayodele; Mohsini, Wajahath; Aung, Sein.

    In: Acta Haematologica, Vol. 119, No. 1, 01.03.2008, p. 8-11.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Acquired factor VIII inhibitor in a patient with dermatomyositis - A case study

    AU - Ayoola, Ayodele

    AU - Mohsini, Wajahath

    AU - Aung, Sein

    PY - 2008/3/1

    Y1 - 2008/3/1

    N2 - Background: Acquired factor VIII inhibitor is an antibody formed against FVIII and seen in patients without FVIII replacement therapy. This entity has been associated with both autoimmune disease and infections. Case Study: We report the case of a 65-year-old man with dermatomyositis who presented with a bleeding episode following venipuncture and hematuria. His coagulation parameters were followed as well as the inhibitor level. His acquired FVIII inhibitor was managed successfully with rituximab. Conclusion: Our patient's bleeding episodes resolved and the inhibitor level was undetectable after 12 months. This is the first case of acquired FVIII inhibitor in association with dermatomyositis.

    AB - Background: Acquired factor VIII inhibitor is an antibody formed against FVIII and seen in patients without FVIII replacement therapy. This entity has been associated with both autoimmune disease and infections. Case Study: We report the case of a 65-year-old man with dermatomyositis who presented with a bleeding episode following venipuncture and hematuria. His coagulation parameters were followed as well as the inhibitor level. His acquired FVIII inhibitor was managed successfully with rituximab. Conclusion: Our patient's bleeding episodes resolved and the inhibitor level was undetectable after 12 months. This is the first case of acquired FVIII inhibitor in association with dermatomyositis.

    UR - http://www.scopus.com/inward/record.url?scp=40549090217&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=40549090217&partnerID=8YFLogxK

    U2 - 10.1159/000112838

    DO - 10.1159/000112838

    M3 - Article

    C2 - 18176073

    AN - SCOPUS:40549090217

    VL - 119

    SP - 8

    EP - 11

    JO - Acta Haematologica

    JF - Acta Haematologica

    SN - 0001-5792

    IS - 1

    ER -